All News
Treat early it is also cheaper!
5 yr cost of RA ttmt
€11250 ACPA+ > €3526 ACPA-
bDMARDS users
€44788 ACPA+ > €40896 ACPA-
ACPA- "late" ttmt 46% more expensive
ACPA+ early vs. late = similar costs
@Rheumnow #EULAR23 POS0369 https://t.co/dg9T9fqJDl
Aurelie Najm AurelieRheumo ( View Tweet)
#EULAR2023 Clinical Highlights. Vasculitis: OP0061 - new US imaging showing vessel inflammation differentiating patients with Behcet’s vs No-BD. OP0304: cohort study showed Benralizumab (IL5 RA) given for eosinophilic asthma also improved BVAS. RCT for EGPA is ongoing @RheumNow https://t.co/7uohfjGk49
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
With the single cell RNA sequencing analysis being my more affordable (relatively) and widely used! Science is moving forward. Highlights in basic science and translational data #EULAR2023 @RheumNow https://t.co/sS7xLeNyLW
Bella Mehta bella_mehta ( View Tweet)
#EULAR2023 Clinical Highlights. SpA: OP0059 H2H RCT of SEC vs ADA Biosimilar in bDMARDs naive showed no difference in imaging progression at 2yrs.
OP0061 Pooled analyses of UPA RCTs showed low rates of Extra-articular Manifestation. Numerically lower vs PBO for Uveitis @RheumNow https://t.co/GoUPfpwTLq
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Biosimilars cost less, but do they incur in indirect costs due to less dis control or more AE?
DANBIO study (>1,300 pts w/ IA)
Costs similar or decreased 9 mo after mandatory switching to ADA biosimilar (GP2017 or SB5)
Decrease 15% GP2017 switchers
#EULAR23 POS0376 @RheumNow https://t.co/bAeqYhNgf0
Aurelie Najm AurelieRheumo ( View Tweet)
#EULAR2023 Clinical Highlights. Osteoarthritis. OP0071 Single centre Phase 2 RCT showed Denosumab halted erosion in Erosive OA at 24 weeks treatment, and the treatment effect enhances after 48 weeks vs PBO @RheumNow https://t.co/YWFUg3cp7P
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Nocicpetor ablation in mice model with #OA - pain was reduced.
If its done before OA progression, it helps, but after it doesnt!
@AM_Malf work highligted at #EULAR2023 @RheumNow https://t.co/zvxHmlCIrD
Bella Mehta bella_mehta ( View Tweet)
#EULAR2023 #LB0005 Can we improve trial design of Bcell depletion in #SLE? Feasibility RCT of RTX in organ specific MSK showed: a)feasible to use ultrasound & clinical as endpoints, b)new tool LAMDA is responsive, c)potential worsening before later improvement with RTX @RheumNow https://t.co/kGDZ6EqLtq
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2023 recommendation update summary from the 2018 in #PsA whats new!
- 3 more drugs now available in PsA. – Guselkumab, Upadacitnib, Risankizumab (1 more in the pipeline)
- safety now to to considered!
- consider the full picture - extraarticular manifestations
@rheumnow https://t.co/7GBILtCX4i
Bella Mehta bella_mehta ( View Tweet)
meds for PsA at #EULAR2023 recommendations
bDMARD after csDMARD (no order proposed)
@RheumNow https://t.co/bHMG4A8nmP
Bella Mehta bella_mehta ( View Tweet)
I hurt because the weather is COLD! Data from Rhumadata in 14000 pt encounters show higher pt GLOBAL in winter vs summer - NB cold in Quebec #EULAR2023 POS0324 @RheumNow Small differences but maybe a script to go south is the right Rx! https://t.co/tjd6FjEHij
Janet Pope Janetbirdope ( View Tweet)
In ERA high BMI is associated with high BMI is assoc with failure to get to Low disease activity. From NORD-STAR RCT. Cdn CATCH cohort in #early #Rheumatoid #arthritis also shows I is associated w less remission and less sustained remission #EULAR2023 @RheumNow POS0324 https://t.co/9EXY8Dyz74
Janet Pope Janetbirdope ( View Tweet)
The thing that can influence bDMARD choice in PsA are the extra-MSK manifestations
“A little bit of a paradigm shift here” - Laure Gossec
2023 @eular_org recommendations
#EULAR2023 @RheumNow https://t.co/gr9IOg1bbj
David Liew drdavidliew ( View Tweet)
Which bDMARD first in PsA?
2023 @eular_org recommendation: no preferred order. All are equal in its eyes
#EULAR2023 @RheumNow https://t.co/6HNNamAj1J
David Liew drdavidliew ( View Tweet)
Predictive model to predict RA status via AI , to know what goes in to model or predictions may change. Ex use of DMARDs https://t.co/fkcEKfZWl8
Janet Pope Janetbirdope ( View Tweet)
PsA recommendations update at #EULAR2023
New overarching principles - should take account of safety
@rheumnow https://t.co/rrZ0ViFRPs
Bella Mehta bella_mehta ( View Tweet)
We would think that targeted therapies would have reduced GC use in RA.
Well, this is not really the case.
Comaprison of GC use in 1999-2008 vs. 2009-2018
52% of patients remain on GC for>3Mo after initiation & 1/3 still continues after 2 years!
@RheumNow #EULAR23 POS0309 https://t.co/dDkUJFlmEm
Aurelie Najm AurelieRheumo ( View Tweet)
Here are the PsA drugs that have come to market in recent years
(and what a few years it’s been)
#EULAR2023 @RheumNow https://t.co/asFsHAD21y
David Liew drdavidliew ( View Tweet)
It might not be perfect, but it’s just great to have a dynamic poster floor back #EULAR2023. The heartbeat of the meeting!
(this was near the end on the last day - it’s been properly hectic throughout) @RheumNow https://t.co/jPGO5dylvg
David Liew drdavidliew ( View Tweet)
PsA update at #EULAR2023 new mechanisms of actions since the 2019 guidelines @RheumNow https://t.co/zaieEHN6sW
Bella Mehta bella_mehta ( View Tweet)
